Institutional Corruption and Pharmaceutical Policy (Harvard Univ Edward J Safra Center For Ethics)
http://www.ethics.harvard.edu/lab/featured/325-jlme-symposium
Institutional Corruption and Pharmaceutical Policy
The goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption that is, widespread or systemic practices, usually legal, that undermine an institutions objectives or integrity. The pharmaceutical industrys own purposes are often undermined. In addition, pharmaceutical industry funding of election campaigns and lobbying skews the legislative process that sets pharmaceutical policy. Moreover, certain practices have corrupted medical research, the production of medical knowledge, the practice of medicine, drug safety, and the Food and Drug Administrations oversight of pharmaceutical marketing.
As a result, practitioners may think they are using reliable information to engage in sound medical practice while actually relying on misleading information and therefore prescribe drugs that are unnecessary or harmful to patients, or more costly than equivalent medications. At the same time, patients and the public may believe that patient advocacy organizations effectively represent their interests while these organizations actually neglect their interests.
To address these issues, a group of lab fellows from the Edmond J. Safra Center put together a symposium of 16 articles that investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs and what is corrupted. The articles address five topics: (1) systemic problems, (2) medical research, (3) medical knowledge and practice, (4) marketing, and (5) patient advocacy organizations. They are now available online and will appear in the fall issue of The Journal of Law, Medicine & Ethics.
<>